Beijing Anshi Biotechnology Co
Anshi Biotechnology is committed to the health service industry and aims to provide patients with high-quality pharmaceutical products
About Beijing Anshi Biotechnology Co
Avistone Biotechnology is a pioneering biopharmaceutical company focused on developing innovative treatments for advanced non-small cell lung cancer (NSCLC) with cMET alterations. Operating in the highly specialized oncology market, Avistone serves patients and healthcare providers by advancing precision medicine through targeted therapies. The company’s business model revolves around the research, development, and commercialization of novel drugs, with revenue generated from clinical trials, licensing agreements, and eventual drug sales. Avistone's flagship products include cMET inhibitors like bozitinib and vebreltinib, which are currently undergoing rigorous clinical trials to ensure efficacy and safety. By leveraging cutting-edge science and strategic partnerships, Avistone aims to address unmet medical needs and improve patient outcomes in the oncology space.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2023 | $138M | $550M | Cathay Capital · Bain Capital · Yanchuang Capital · IDG Capital | ↗ |
Growth signals
Latest recorded traffic for Beijing Anshi Biotechnology Co is 920 monthly website visits, up 240.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Anshi Biotechnology Co in its local ecosystem
The Beijing Anshi Biotechnology Co office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
IDG Capital
SDIC Fund Management
Cathay Capital
Bain Capital
Yanchuang Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Anshi Biotechnology Co on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Anshi Biotechnology Co’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








